Kronox Lab Sciences makes the invisible ingredients that go inside things people swallow, inject, or measure with - the ultra-pure powders behind a paracetamol tablet, a protein shake, or a lab test - and it has spent over fifteen years quietly turning that narrow craft into a debt-free, three-plant operation with a fourth on the way. The company was born in 2008 in Gujarat, started manufacturing in a leased shed in 2009, and listed on the Indian exchanges in mid-2024, all while sticking to a single playbook: make a very wide range of very pure chemicals, sell them to regulated industries that hate switching suppliers, and never borrow a rupee to do it. That recurring approach - multi-product purity at scale, served from a tight cluster of plants near the customer base - explains everything that follows.
Business segments
A single engine built on one manufacturing logic - over 185 high-purity chemical products made across three neighbouring plants, sold into industries from pharmaceuticals to solar energy, with a fourth plant now cleared for construction.
1. High-purity specialty fine chemicals: the ingredient behind the pill, the powder and the panel
The company makes the purified chemical salts and compounds that regulated industries use as raw materials - and because those customers need batch-to-batch consistency and regulatory paperwork, once a supplier is qualified, it tends to stay qualified.
- Over 185 products, one manufacturing backbone - the portfolio spans phosphates, sulphates, acetates, chlorides, citrates, nitrates, EDTA derivatives, gluconates and more, all made on shared equipment across three plants clustered within a kilometre of each other in Padra, Gujarat, so a single logistics and quality team can serve the entire range.
- Sold where purity is non-negotiable - end markets include pharmaceuticals (APIs and formulations), nutraceuticals, biotech, scientific research, food chemicals, personal care, agrochemicals, metallurgy and animal health; the same chemical can ship in different grades - IP, BP, USP, FCC, ACS - depending on whether it is going into a medicine, a food supplement or a laboratory reagent.
- Custom particle size as a differentiator - products are available in mesh sizes from 10 to 100, and the company accepts custom manufacturing specifications, which means a pharma customer can order a citrate ground exactly the way its formulation line needs it, rather than adapting its process to an off-the-shelf powder.
- Certifications open the door to regulated buyers - the facilities hold FSSC 22000, GMP, GLP, ISO 9001, ISO 14001 and ISO 45001 certifications, and products are certified Kosher and Halal where applicable; these are not marketing badges but hard requirements before a nutraceutical or food-chemical customer can place an order.
- Export reach built patient-seller relationships - exports accounted for roughly a quarter of revenue in FY24, and the company has long-term supply commitments with customers both in India and abroad, the kind of arrangements that take years to build because each new product-customer pair requires qualification batches and stability testing.
Group structure and partners
A founder-led, zero-debt company with no subsidiaries - the entire business sits inside one listed entity, and the three executive directors between them cover operations, finance, and sales.
- Promoter-operators with domain depth - Chairman and Managing Director Jogindersingh Jaswal brought over three decades of chemical-industry experience including prior stints at Ranbaxy Laboratories and Ranbaxy Fine Chemicals; Whole-time Directors Ketan Ramani (finance, purchase, administration) and Pritesh Ramani (sales and marketing) are brothers, each with more than twenty years in the business.
- No subsidiaries, no joint ventures - the company is exclusively engaged in chemical manufacturing and operates as a single legal entity with no associate companies, which means all assets, cash flows and liabilities sit in one place.
- Zero borrowings as a structural choice - as of March 2024 the company carried no debt on its books, a rare profile in a capital-intensive manufacturing industry and one that gives it the freedom to fund the upcoming Dahej plant without pressure from lenders.
- A fourth plant fully cleared - the company holds a 99-year lease on 20,471 square metres of land at GIDC Dahej-II in Gujarat’s chemical zone, and by November 2025 it had secured Environmental Clearance from the Central Government and Consent to Establish from the Gujarat Pollution Control Board, with construction set to begin.